Actinium Pharma's (ATNM) Iomab-B Granted EMA Orphan Designation in r/r AML
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks hit by tech slide; yen flails at intervention zone
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Iomab-B
October 18, 2016 7:00 AM EDT- Orphan designation is expected to provide increased communication and guidance from regulators and 10-year market exclusivity should marketing authorization be obtained
-Â Orphan designation for Iomab-B follows SME (small or medium-sized enterprise) status, which was granted in August 2016
- Iomab-B now has orphan designation in the US and EU
NEW YORK, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the... More
